New York State Common Retirement Fund’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-185,317
| Closed | -$6.2M | – | 3312 |
|
|
2026
Q1 | $6.2M | Hold |
185,317
| – | – | 0.01% | 928 |
|
|
2025
Q4 | $8.58M | Buy |
185,317
+169,717
| +1,088% | +$9.31M | 0.01% | 799 |
|
|
2025
Q3 | $1.05M | Buy |
15,600
+360
| +2% | +$26.7K | ﹤0.01% | 1672 |
|
|
2025
Q2 | $1.28M | Buy |
15,240
+7,523
| +97% | +$563K | ﹤0.01% | 1577 |
|
|
2025
Q1 | $551K | Hold |
7,717
| – | – | ﹤0.01% | 1859 |
|
|
2024
Q4 | $347K | Buy |
7,717
+900
| +13% | +$46.6K | ﹤0.01% | 2069 |
|
|
2024
Q3 | $344K | Sell |
6,817
-2,300
| -25% | -$110K | ﹤0.01% | 2085 |
|
|
2024
Q2 | $372K | Buy |
9,117
+8,980
| +6,555% | +$381K | ﹤0.01% | 2166 |
|
|
2024
Q1 | $5.86K | Hold |
137
| – | – | ﹤0.01% | 3209 |
|
|
2023
Q4 | $5.51K | Buy |
+137
| New | +$3.9K | ﹤0.01% | 3213 |
|
|
2021
Q3 | – | Sell |
-35
| Closed | -$1K | – | 3504 |
|
|
2021
Q2 | $1K | Sell |
35
-3,478
| -99% | -$58.8K | ﹤0.01% | 3463 |
|
|
2021
Q1 | $66K | Hold |
3,513
| – | – | ﹤0.01% | 3164 |
|
|
2020
Q4 | $102K | Hold |
3,513
| – | – | ﹤0.01% | 3016 |
|
|
2020
Q3 | $132K | Hold |
3,513
| – | – | ﹤0.01% | 2822 |
|
|
2020
Q2 | $117K | Buy |
+3,513
| New | +$152K | ﹤0.01% | 2873 |
|
New York State Common Retirement Fund's SLNO Position: Q2 2026 in Review
New York State Common Retirement Fund sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 185,317 shares — an estimated $6.2M sold.
New York State Common Retirement Fund first reported a position in SLNO in Q2 2020 and held it in 15 quarters. The position peaked at $8.58M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- New York State Common Retirement Fund reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- New York State Common Retirement Fund sold 185,317 Soleno Therapeutics shares in Q2 2026, an estimated $6.2M.
- New York State Common Retirement Fund first reported a position in Soleno Therapeutics in Q2 2020 and held it in 15 quarters.
- New York State Common Retirement Fund's Soleno Therapeutics position peaked at $8.58M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.